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ABSTRACT
Small non-coding RNAs, in particular
microRNAs(miRNAs), regulate fine-tuning of gene
expression and can act as oncogenes or tumor sup-
pressor genes. Differential miRNA expression has
been reported to be of functional relevance for
tumor biology. Using next-generation sequencing,
the unbiased and absolute quantification of the
small RNA transcriptome is now feasible.
Neuroblastoma(NB) is an embryonal tumor with
highly variable clinical course. We analyzed the
small RNA transcriptomes of five favorable and
five unfavorable NBs using SOLiD next-generation
sequencing, generating a total of >188000000
reads. MiRNA expression profiles obtained by
deep sequencing correlated well with real-time
PCR data. Cluster analysis differentiated between
favorable and unfavorable NBs, and the miRNA tran-
scriptomes of these two groups were significantly
different. Oncogenic miRNAs of the miR17-92
cluster and the miR-181 family were overexpressed
in unfavorable NBs. In contrast, the putative tumor
suppressive microRNAs, miR-542-5p and miR-628,
were expressed in favorable NBs and virtually
absent in unfavorable NBs. In-depth sequence
analysis revealed extensive post-transcriptional
miRNA editing. Of 13 identified novel miRNAs,
three were further analyzed, and expression could
be confirmed in a cohort of 70 NBs.
INTRODUCTION
Small non-coding RNAs, in particular microRNAs
(miRNAs), have been identiﬁed to regulate global gene
expression patterns. MiRNAs are transcribed as long pre-
cursors and then cleaved to pre-miRNAs of characteristic
hairpin structure. Pre-miRNAs are further processed to
generate mature miRNAs. For several pre-miRNAs,
both strands are processed and give rise to a functional
miRNA. If either one is known to be expressed at <15%
of the other form, it is designated as miRNA* (star form).
If the expression ratio is not known, a mature miRNA is
designated with suﬃx ‘-3p’ or ‘-5p’, depending on the
originating strand.
Functional miRNAs regulate the translation and
cleavage of mRNAs by sequence-speciﬁc interaction with
the 30-UTR [reviewed in (1)]. MiRNAs are involved in the
regulation of most physiological processes, including dif-
ferentiation, development and apoptosis (2). In cancer,
miRNAs may exert oncogenic function by inhibiting
tumor suppressor genes or may act as tumor suppressors
by inhibiting oncogenes (3,4).
Neuroblastoma (NB) is the most common extracranial,
solid tumor of childhood, comprising 15% of childhood
cancer deaths [reviewed in (5–7)]. NB is characterized by a
broad clinical and biological heterogeneity. Patients with
favorable NB have a very good prognosis as tumor regres-
sion or diﬀerentiation is often observed even in the
absence of speciﬁc treatment. In contrast, most patients
with highly aggressive NB, often characterized by ampli-
ﬁcation of the MYCN oncogene, die despite intensive
therapy. Most recently, attempts were made to analyze
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Several groups analyzed miRNA expression in primary
NBs using miRNA microarrays or high-throughput
RT-qPCR. They reported broad deregulation of miRNA
patterns correlated with MYCN ampliﬁcation, 11q
deletion and prognosis (9,15,16,19). Further functional
analysis identiﬁed miRNAs of the MYCN-regulated
miR-17-92 cluster to be important for proliferation and
migration as well as invasive growth of NB cells (12, 17).
Furthermore, miR-34a, located in a region of frequent
chromosomal loss, appears to directly downregulate ex-
pression of the MYCN oncogene (10,18,19). The only
attempt to clone NB-speciﬁc miRNAs from primary
tumors was compromised by the low coverage of the
generated libraries (8).
With the availability of high-throughput next-
generation sequencing (NGS) (24–28), the technical draw-
backs of probe-based methodologies, especially restriction
to detection of only previously known sequences, can be
overcome. As miRNAs are sequenced directly, informa-
tion about SNPs as well as post-transcriptional RNA
editing, 30-terminal addition of single nucleotides and vari-
ation in miRNA length becomes available for further
analysis (13,26,29). It has become evident that
post-transcriptional modiﬁcations of miRNAs produce
multiple mature variants, which are referred to as
isomiRs (26). NGS of the small RNA transcriptome also
provides data on the expression of other small RNAs,
such as piRNAs, snoRNAs and other less well
characterized short, regulatory RNAs that do not meet
the criteria of miRNAs (30).
We compared the small RNA transcriptomes of ﬁve
favorable and ﬁve unfavorable, MYCN-ampliﬁed NBs
by means of ultra-deep NGS using the SOLiD system
(Applied Biosystems). NGS results were compared with
miRNA expression patterns generated for the same
samples by high-throughput RT-qPCR to correlate
results from both systems and validate miRNA expression
patterns (14). Favorable and unfavorable NBs were dis-
tinguishable by hierarchical clustering of miRNA
patterns. Expression of single miRNAs also diﬀered sig-
niﬁcantly between the two groups. We subsequently
analyzed RNA editing as well as occurrence and frequency
of isomiR expression, and identiﬁed 13 candidates for
novel miRNAs of which three were further validated in
70 primary NBs using RT-qPCR. To our knowledge, this
is the ﬁrst comprehensive presentation of the composition
of the small RNA transcriptome of a primary tumor,
using NB as a model system. By comparing tumors of
divergent biology and clinical outcome, we also provide
insights into the heterogeneity of the small RNA tran-
scriptomes in cancer.
MATERIALS AND METHODS
Sample preparation and RNA isolation
Written informed consent was obtained from all patients’
representatives, and the study was approved by the insti-
tutional review board. Serial cryosections were obtained
from all tumors. The ﬁrst and last cryosections of each
series were used to verify tumor cell content. Samples
were only included in this study if the tumor cell content
was >70 %. No systematic diﬀerence in tumor cell content
was observed between samples from unfavorable and fa-
vorable NBs included in this study. Cryosections not used
for histological analysis were transferred to TRIzol
(Qiagen, Hilden, Germany), and total RNA was extracted
using the miRNEASY kit (Qiagen) according to the
manufacturer’s recommendations.
Small RNA library generation and sequencing
Libraries for deep sequencing were prepared from total
RNA according to the manufacturer’s protocol [SREK
(small RNA expression Kit), Applied Biosystems, Foster
City, CA, USA]. Library integrity was controlled using a
DNA 1000 Lab Chip on a Bioanalyzer (Agilent, Santa
Clara, CA, USA). Template bead preparation, emulsion
PCR and deposition was performed according to the
standard protocol, and slides were analyzed on a SOLiD
system V3 (Applied Biosystems).
Sequence processing and mapping
Mapping of SOLiD reads was performed using MAQ
0.7.1-10 (Subversion revision 687). We allowed two
mismatches for read lengths between 12 and 14 and
three mismatches for longer reads. Raw expression
values (read counts) were obtained by summing the
number of reads that mapped uniquely to one of the ref-
erence databases, Human Genome RefSeq Hg18,
miRBase release 13.0, fRNAdb v3.1, RepBase 14.06,
human UniGene sequences (July 2009) and Escherichia
coli (NCBI Nucleotides accession no. NC_000913). The
conﬁdence in a correct assignment of reads to mature
miRNAs was substantially increased by discarding reads
not uniquely mappable and by the error-correcting
properties of SOLiD sequencing. See Supplementary
Figure S1 for more details.
Normalization of read counts
To quantify and compare miRNA expression across
datasets, raw read counts were normalized using linear
transformations of each dataset. One dataset was chosen
arbitrarily as a reference, and quantile–quantile (qq) plots
of the distribution of absolute count values >5 against all
remaining datasets were compared in logarithmic space.
The median of diﬀerences of corresponding quantile
values of a dataset and the reference were computed.
This corresponds to a pure scaling normalization, and de-
termines the scaling factor in a robust manner from the
qq-plot (S1,S4).
MiRNA RT-qPCR
Total RNA (20ng) was reverse transcribed using the
Megaplex RT stem–loop primer pool (Applied
Biosystems), enabling miRNA-speciﬁc cDNA synthesis
for 430 diﬀerent human miRNAs and 18 small RNA
controls. Subsequently, Megaplex RT products were
5920 Nucleic Acids Research, 2010,Vol.38, No. 17ampliﬁed using a two-step strategy described previously
(14). All reactions were performed on the 7900 HT
(Applied Biosystems) using the gene maximization
strategy (14). MiRNA RT-qPCR data were normalized
as previously described (15). In contrast to the known
miRNAs, PCR reactions for Seq 2, 6 and 12 were per-
formed in a singleplex format. All RT-qPCR assays
were performed according to the MIQE guidelines (31),
and respective information is provided in the supporting
material (Supplementary Figure S12). In singleplex and
multiplex assays, miRNAs with Ct (cycle threshold)
values >40 or >35, respectively, were considered absent.
Normalized expression values are reported in
Supplementary Figure S13 (‘NaN’ if the miRNA was
absent).
Statistical testing and cluster analysis
R 2.9.1 (http://www.r-project.org) was used for statistical
and clustering analysis. The rawp2adjp (raw P-value to
adjusted P-value) function of the R library multtest was
used for Benjamini–Hochberg multiple testing correction
(32,33). To assess the amount of 30-editing in mature
miRNAs, the nucleotide distribution (categories: A, C,
G, T, missing) at each position in each miRNA in every
dataset was obtained. To test for diﬀerential 30-editing, the
nucleotide distributions were computed for each position
in each miRNA in each class, and the numbers were
aggregated over the ﬁve patients in each class. To
compare nucleotide distributions in the Death of
disease(DoD) and event-free survival(EFS) patient
groups (for ﬁxed miRNA and ﬁxed position), a chi
square statistic was computed as a diﬀerence measure
for miRNAs displaying >50 counts in each of both
groups. Class labels were permuted in all 252 possible
combinations, and the rank of the test statistic of the
true class labels was converted into an empirical
P-value. Hierarchical clustering was performed based on
Canberra distances, which allows to compare sequencing
data of diﬀerent orders of magnitude without
log-transformation.
RESULTS
Sequencing of the non-coding RNA transcriptomes
of 10 NBs
Small RNA transcriptomes from ﬁve NBs with favorable
biology and ﬁve MYCN-ampliﬁed NBs with unfavorable
biology [(patients had maximum divergent clinical
courses: EFS or DoD, Table 1) were analyzed by NGS
using the SOLiD sequencer (Applied Biosystems)]. A total
of 188821076 sequencing reads were obtained. Of all
reads analyzed, 57% contained no adapter sequence,
indicating that a fragment of at least 35nt was sequenced.
Read length distribution after adapter removal revealed
four peaks at 12, 17, 21–23 and 35nt (Figure 1A and
Supplementary Figure S2). This peak distribution was
consistent with results from other ncRNA deep
sequencing runs with the same system. The peak at
21–23nt indicates that mature miRNAs were enriched in
the sequenced samples.
Library composition and mapping results
Library composition was determined by mapping all reads
longer than 12nt to the human genome. Annotation was
based on annotation tracks included in the UCSC genome
browser, the functional RNA database, fRNAdb (34) and
miRBase (35). MiRNAs were identiﬁed and quantiﬁed by
simultaneously mapping reads against the human genome,
pre-miRNAs in miRBase and mature miRNAs in
miRBase. About 40 % of the sequences were mappable
using this approach. Unmappable sequences were neither
repetitive, nor represented unknown transcripts, nor were
due to contamination, as they rarely mapped against
RepBase (36), UniGene transcript clusters (37) or the
E. coli genome. The vast majority of these unmapped
reads of unknown origin were 35nt long, which was the
maximum detectable length in this experimental setting.
Absence of the adapter sequence indicated that the
original sequence probably exceeded 35bp.
The average ratio of mRNA/ncRNA was about 1:5
among mappable reads (Figure 1B). The proportion of
miRNAs among the non-coding RNA ranged from
30 to >80%, with tRNA being the other major ncRNA
species (Figure 1C). On average, 5% of all sequences
(range 2.6–12.1%) were identiﬁed as mature miRNAs
and 6.1% as pre-miRNAs. The absolute number of
reads and the fraction mapped to mature miRNAs
varied across the datasets (Supplementary Figure S3). A
trend toward a higher proportion of mature miRNAs in
tumors from EFS patients was detected (65% versus
55%), but was not signiﬁcant due to the low number of
cases analyzed. In summary, most of the mappable se-
quences were non-coding RNAs, with miRNAs being
the major constituent.
Among those reads successfully mapped to mature
miRNAs, 6.3% of all positions in SOLiD color space
did not match the reference sequence. After conversion
of data from color to nucleotide space, 2.6% mismatches
remained. This fraction includes sequencing errors as well
as SNPs and post-transcriptional editing events. Technical
sequencing errors were equally distributed over all pos-
itions analyzed and were well below the rate of
Table 1. Clinical and molecular data for NB patients included in this
study
Pat. no. Stage Age at Dx MNA DoD EFS OS
552 1 405 0 0 3109 3109
553 1 481 0 0 3745 3745
554 1 961 0 0 3605 3605
555 1 459 0 0 2861 2861
556 1 103 0 0 2856 2856
557 4 1478 1 1 946 1375
558 4 496 1 1 351 539
559 4 1045 1 1 839 1115
560 4 978 1 1 184 212
561 4 4827 1 1 201 207
Stage, INSS Stage; age at Dx, Age at diagnosis (days); MNA, MYCN
ampliﬁcation status (0: MYCN not ampliﬁed, 1: MYCN ampliﬁed);
DoD: Death of Disease (0: alive, 1: dead); EFS, Event-free survival
(days); OS, Overall survival (days).
Nucleic Acids Research, 2010,Vol.38, No. 17 5921mismatches caused by SNPs and post-transcriptional
editing events (Figure 3D and Supplementary Figure S1).
Correlation of miRNA sequencing counts to
RT-qPCR results
Sequencing counts were normalized (Supplementary
Figure S1 and S4) between datasets to account for raw
counts of diﬀerent magnitudes. To independently
validate miRNA deep sequencing data, we examined the
correlation between normalized sequencing counts and ex-
pression determined by RT-qPCR. The Pearson’s correl-
ation coeﬃcient between sequencing and RT-qPCR data
was calculated for 204 miRNAs across the 10 patients.
Expression of most miRNAs was highly correlated
between the technical platforms (Figure 1D). This was
also conﬁrmed on the level of individual datasets
(Supplementary Figure S5), with Pearson’s correlation co-
eﬃcients ranging from 0.57 to 0.67 for each tumor. We
conclude that normalized expression values obtained from
miRNA deep sequencing are valid and comparable to
RT-qPCR data.
Analysis of known NB-related miRNAs
We ﬁrst analyzed miRNAs previously reported to be dif-
ferentially expressed in NB, comprising all miRNAs of the
miR-17-92 cluster (9,15–17), miRNAs of the miR-181
family (9), miR-542-5p [(20) and Schulte et al, submitted
for publication] and miR-628-5p (21). Diﬀerential expres-
sion of these miRNAs between favorable and unfavorable
NBs were consistent with published results (Figure 2A).
Absolute quantiﬁcation using NGS revealed that the
oncogenic miRNAs of the miR17-92 cluster and the
miR-181 family, which were previously shown to be
upregulated in unfavorable NB (9), were also readily de-
tectable in favorable NBs. The putative tumor-suppressive
miR-542-5p and miR-628-5p were moderately expressed
in favorable NBs, and nearly absent in unfavorable NBs.
MiR-34a, which has been described to have tumor-
suppressive functions, was not diﬀerentially expressed in
favorable versus unfavorable NBs in this study. Taken
together, all miRNAs previously linked to NB biology
were also identiﬁed in this study.
Unbiased analysis of mature miRNAs discriminating
favorable from unfavorable NB
We aimed to identify other miRNAs diﬀerentially ex-
pressed in favorable versus unfavorable NB using an
unbiased approach. Only mature miRNAs represented
by more than ﬁve raw counts in at least ﬁve datasets
were considered. These criteria were met by 465
miRNAs, including 105 miRNA* and 45 miRNA-3p se-
quences. A total of 76 miRNAs were diﬀerentially ex-
pressed based on a t-test (uncorrected P<0.05). See
Figure 2B for the top 40 miRNAs. In an unsupervised
cluster analysis, these 76 miRNAs separated the EFS
and DoD classes (Figure 2C). Classes were still separated
when all 465 expressed miRNAs were used
(Supplementary Figure S6).
Due to the small sample size, only miR-181a-2*
remained statistically signiﬁcant when Bonferroni
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Figure 1. NGS of the small RNA transcriptome. (A) Read length distribution (nt) after adapter removal. The y-axis depicts the percentage of read
lengths relative to the total number of reads in each dataset, averaged over all datasets. The peak at length 35 is oﬀ scale, its actual height is 57%.
Read lengths too short for mapping are shown in gray. (B) Proportion of non-coding (green) versus coding (yellow) RNA for each sample.
The proportion of ncRNA is >80% in all but two samples analyzed. (C) Distribution of ncRNA species in the samples analyzed. (D) Histogram
of Pearson’s correlation coeﬃcients between logarithmic normalized miRNA expression values derived from sequencing versus negative normalized
RT-qCt values (15) (displayed for 204 miRNAs available for comparison).
5922 Nucleic Acids Research, 2010,Vol.38, No. 17correction for multiple testing was applied. However, the
frequency of low P-values for diﬀerential expression was
higher than expected assuming a random distribution
(Figure 2D). This P-value distribution indicates diﬀeren-
tial miRNA expression patterns in favorable versus un-
favorable NBs.
Expression of miRNAs from the 50 and 30 arms of
pre-miRNAs
We analyzed the ratios of expressions of miRNAs from
50 and 30 arms of pre-miRNAs. First, we examined
miRNAs previously linked to NB biology (Figure 3A)
and observed that all miR*/miR pairs (3–9 in
Figure 3A) were found, as expected, at ratios below
15%. We furthermore noted a linear correlation of loga-
rithmic expressions (r=0.75). For the two miR-5p/
miR-3p pairs, no clear bias toward one form was
observed (1–2 in Figure 3A). When analyzing all miR*/
miR pairs, 60.6% of all pairs show a ratio of <15%.
(Figure 3B). For miRNAs with high abundance ( 100
counts for at least one sibling), this is true for 79%.
Expression values of all mir-5p/miR-3p pairs are shown
in Figure 3C. Here, for 37.3% of all pairs, the expression
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Figure 2. Diﬀerential miRNA expression between favorable and unfavorable NB is presented as strip chart of normalized read counts. (A,B) Values
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to DoD datasets. (A) Expression data (normalized counts) for known NB-associated miRNAs. (B) Expression data (normalized counts) for the 40
best class-separating miRNAs. Rows are sorted according to raw p-values. These data indicate that previously NB-associated miRNAs (e.g. miR-17
and miR542-5p) as well as newly identiﬁed miRNAs are diﬀerentially expressed between favorable and unfavorable NB. (C) Heat map and cluster
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Nucleic Acids Research, 2010,Vol.38, No. 17 5923ratio is either <0.15/1 or >1/0.15 suggesting that those
could rather represent miR/miR* pairs. Further studies
are warranted to investigate whether these results are
commonly found or if they are speciﬁc for cancer or
even for NB. In some instances, the -3p form was predom-
inant; e.g. hsa-miR-324-3p had on average >200-fold
higher expression counts than hsa-miR-324-5p.
In Figure 3, no global diﬀerence between DoD and EFS
classes with respect to use of the diﬀerent miRNA forms is
obvious. To identify possible diﬀerences on the level of
individual pairs, we performed t-tests for all 117 pairs
(comprising 38 miR-5p/miR-3p and 79 miR/miR* pairs).
After correction for multiple testing using the
Benjamini–Hochberg method, no signiﬁcant results
remained (Supplementary Figure S10).
Analysis of editing of mature miRNAs
Editing of miRNAs has been reported to occur frequently
(27). In our dataset, mismatches with regard to the refer-
ence sequence were highly biased toward the 30-end of
sequenced miRNAs, in line with previous reports of
miRNA editing (13). Additionally, missing nucleotides
at the 30-end of mature miRNAs were also observed, as
well as terminal additions of nucleotides (Figure 3D,
Supplementary Figure S11C).
The technical sequencing error rate is well below the
rate of mismatches and remains approximately constant
across miRNA positions (Supplementary Figure S1). We
also ruled out that mismatches can be explained by
spurious editing sites due to homology to other miRNAs
or tRNAs (38), . Most of the sequencing errors are cor-
rected during conversion from SOLiD color space to nu-
cleotide space and our mapping algorithm excludes
ambigous reads instead of allocating them randomly.
We also observed a substantial number of ‘A to I’
editing events (0.7%). However, further substantial
amounts of editing events were observed for G!A
(1.5% of all uniquely mapped reads), U!C (1.2%) and
U!A (1.1%). Among the miRNAs undergoing A to I
editing were miR-376a and miR-376c, miRNAs with pre-
viously described editing sites (Supplementary Figure
S11B) (38,39). Individual miRNAs were diﬀerentially
30-edited in favorable and unfavorable NBs, including
hsa-miR-337-3p (P=0.008 at position  1, P=0.004 at
position  2), hsa-miR-17*, and hsa-miR-301a (P=0.008
at positions  1 and  2 for both miRNAs). However, no
signiﬁcant global diﬀerence in miRNA editing was
detected between the two groups as histograms of empir-
ical P-values for each nucleotide position resembled a
uniform distribution (Supplementary Figure S7).
Terminal additions were found in 29.1% of all uniquely
mapped miRNAs and the majority of these additions
(63.1%) were non-template additions. Of those, single nu-
cleotide terminal additions were predominant (67.2%).
Addition of two or three bases was observed in 27.3%
and 5.5%, respectively. In summary, most of these add-
itions were single-nucleotide non-template adenosine or
uracil additions (Supplementary Figure S11C), in accord-
ance with published datasets (13,24,40,41).
In addition to the ﬁrst description of miRNA terminal
additions in NB, our study conﬁrmed that editing of
miRNAs was mainly restricted to the 30 end, and that
diﬀerential editing between favorable and unfavorable
NBs was detectable for single miRNAs, but not as a
global phenomenon.
Prediction of putative new miRNAs
To discover hitherto unknown miRNAs, a customized,
eﬃciency-improved version of the miRDeep software
package (42) was developed to analyze all reads mapped
to the human genome. Since miRDeep utilizes no infor-
mation on known miRNAs, de novo discovery of miRNAs
B
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5924 Nucleic Acids Research, 2010,Vol.38, No. 17is performed. MiRDeep provides a score integrating dif-
ferent measures of prediction quality, with a score of >1.0
being a good indicator for a true pre-miRNA
(Supplementary Figure S8). In total, 64% of predicted
miRNAs exactly matched an entry in miRBase. Of
non-perfect matches, 24 sequences contained no known
miRNA motifs, and were represented in at least three
diﬀerent datasets. A BLAST search revealed little or no
homology to described miRNA sequences (E-value>0.1)
for 13 of these 24 sequences, which represent strong can-
didates for new miRNAs (Supplementary Figure S9,
Figure 4A). Of these potential novel miRNAs, three
miRNAs were selected for validation based on diﬀerential
expression levels (Seq 6 and Seq 12) or high expression
levels (Seq 2). Prediction of RNA secondary structures
revealed a stem–loop conﬁguration for all three sequences
(Figure 4B). RT-qPCR conﬁrmed detectable expression
of Seq 2 in 69 out of 70 primary NBs (Supplementary
Figure S13). Furthermore, expression of Seq 6 or high
expression of Seq 12 were associated with adverse
outcome in Kaplan–Meier analysis (Figure 4C). These
ﬁndings underscore the power of sequencing approaches
in discovering novel transcriptional units.
DISCUSSION AND CONCLUSION
NGS is an ideal method to identify transcripts in an
unbiased and unselected fashion. It does not require a
priori knowledge of the sequence of the RNA species to
be detected, but provides exact sequence information. In
addition, NGS allows for absolute and exact quantiﬁca-
tion. Reports on deep sequencing of the RNAome and
some of the technical diﬃculties encountered have been
published (24–28). It was recently shown that miRNA
sequencing using the SREK protocol diﬀers from
sequencing of libraries that rely on ligation of ‘modban’
adapters (25,43). In contrast to library generation,
sequencing alone appears to introduce only a minor bias
into the process of NGS. Therefore, diﬀerent strategies of
RNA species pre-selection and adapter ligation should be
evaluated using independent validation methods, e.g.
RT-qPCR.
To the best of our knowledge, this is the ﬁrst study to
compare the small RNA transcriptomes in biological
groups on a statistical basis. For this purpose, we used
10 primary NBs with very heterogeneous clinical courses
and compared patients cured of their disease to patients
who died from the tumor. We detected signiﬁcant and
speciﬁc diﬀerential miRNA expression in these two
groups. Cluster analyses were able to separate the
groups exactly. This ﬁnding supports the notion that
tumor aggressiveness is reﬂected in the miRNA
transcriptome.
We further focused on the analysis of miRNAs that
were previously proposed to be diﬀerentially expressed
between favorable and unfavorable NBs. The miRNAs
of the miR-17-92 cluster are expressed as a long
primary, polycistronic transcript, and are prototypic of
oncogenic miRNAs [reviewed in (16)]. The miR-17-92
cluster is suﬃcient to transform hematopoetic cells (44),
and is regulated by transcription factors of the MYC
family (15,45). In NB, miR-17-92 expression correlates
with MYCN ampliﬁcation and adverse outcome (9,16),
which was also conﬁrmed in the data presented here.
Our study is also the ﬁrst to report absolute expression
data of the miR-17-92 cluster in malignant tumors.
Interestingly, the tumor-suppressive miRNAs, miR-
542-5p and miR-628, are moderately expressed in favor-
able NBs and nearly absent in unfavorable NBs. The role
of known players of the small RNAome in NB was con-
ﬁrmed in this study, and these miRNAs were absolutely
quantiﬁed for the ﬁrst time.
We also used an unbiased approach to analyze other
miRNAs diﬀerentially expressed between the two diver-
gent clinical groups in our study. Comparing the distribu-
tion of raw P-values to the uniform distribution expected
for random data revealed an enrichment of small P-values
(Figure 2D), indicating a principle diﬀerence between
the small miRNA transcriptomes of favorable and
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Figure 4. (A) Expression levels of putative new miRNA in favorable
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Nucleic Acids Research, 2010,Vol.38, No. 17 5925unfavorable NB. This observation was further supported
by the fact that clustering based on all miRNAs resulted in
a robust separation of both groups (Supplementary
Figure S6). However, identiﬁcation of single diﬀerentially
expressed miRNAs were complicated by the small number
of cases analyzed. After correction for multiple testing,
only one miRNA, miR-181a-2*, remained signiﬁcant.
We therefore report the 40 most diﬀerentially expressed
miRNAs ranked according to their raw P-values
(Figure 2B). A substantial number of miRNAs among
the 40 most diﬀerentially expressed miRNAs show expres-
sion patterns in accordance with published results. These
miRNAs include miR-25 (20), miR-181a (9), miR-542-5p
(20), miR-324-5p (9), miR-628-3p (21), miR-323-5p (9,20),
miR-654 (20), miR-190 (20) and miR-149 (20). In contrast
to Loven et al. (46), we here report miR-199 to be
upregulated in unfavorable NB. However, while Loven
et al. solely refer to an in vitro system, we previously
reported miR-199 to be upregulated in an independent
cohort of MYCN-ampliﬁed unfavorable primary tumors
(16), supporting our current results. Most surprisingly,
several miR* forms were identiﬁed among these
miRNAs, including miR-181a-2*, which was also ex-
pressed at very high absolute levels. The high number
and abundance of miR* forms is consistent with recent
reports (24,26,47), and motivated us to further analyze
the expression of miR-5p/-3p pairs in our dataset.
Interestingly, there was a high correlation of the expres-
sion ratios of miR and respective miR* forms in miRNAs
previously reported to be diﬀerentially expressed in NB
(Figure 2A). Expression of these miRNA pairs reﬂected
the expected expression ratio of miR*/miR pairs below
0.15. When all miRNAs were considered (Figure 3B), we
found that some star forms are expressed at higher levels
than their non-star counterparts, but we note that this is
mainly restricted to miRNAs with overall low expression.
Therefore, the observed results are in agreement with the
naming convention. One could have hypothesized that this
might be diﬀerent in tumors, but our data provide no
evidence for this in NB. Finally, we focus on miR-3p
versus miR-5p expression (Figure 3C), as in NB neither
the expression of most miR-3p forms nor the ratio
between miR-5p and -3p has been analyzed before. In
general, we observe higher expression of miR-3p than
miR* as compared to their respective siblings, which is
again consistent with the naming convention. Although
the presence and in very few instances high abundance
of miR-3p has been described before, we here conﬁrm
this ﬁnding in NB and report some miRNAs with remark-
ably high miR-3p/-5p ratios in NB (e.g. miR-324). On the
other hand, some miR-3p/-5p ratios are very low, and our
ﬁndings might hint at the fact that these miRNAs have to
be reclassiﬁed. Most interestingly, no systematic diﬀer-
ences were found in miR-5p/-3p ratios observed between
the clinically deﬁned EFS and DoD groups analyzed here.
Nevertheless, diﬀerences for single miRNAs with regard
to the corresponding sibling were identiﬁed between these
two groups, but did not remain signiﬁcant after multiple
testing correction (Supplementary Figure S10). We
conclude that the relative stability of both miRNA
forms is either not regulated diﬀerentially in NB of
divergent clinical course or that diﬀerences are subtle
and can only be detected in a larger cohort.
Sequencing-based approaches can also give insight into
ﬁne tuning of miRNA expression by editing. We conﬁrm
previous ﬁndings that editing of miRNAs is most prom-
inent at the 30-end (27). Although a substantial proportion
of editing events detected in this study can be explained by
the previously described A to I editing, other editing
events (e.g. G to A) detected here have not yet been
described, and the mechanisms involved remain elusive.
The most frequently edited positions are  1 and  6 (pos-
itions with regard to the 30-end found in miRBase).
Surprisingly, base changes at position  6 were consistently
observed more often than base changes at position  1. It
remains to be elucidated whether this is a biological phe-
nomenon or reﬂects an inherent breakpoint. The latter
hypothesis is supported by the observation that a major
miRNA-like fraction of size 17bp was detected
(Figure 1A). Regarding inconsistencies with reference
miRNA sequences, we also detected missing bases at pos-
itions  1 and  2 as well as terminal additions, mainly of
the nucleotides A and U (Supplementary Figure S11 for
details). The latter phenomenon is consistent with
previous reports (13,24,40,41) and might be involved in
stabilization of the respective miRNAs. Of note, no dif-
ference was observed between favorable and unfavorable
NB. It has to be emphasized that the conservative
mapping approach used in this study also prevented
the detection of spurious editing sites due to homology
of miRNAs and tRNAs (detailed description of editing
events are included as Supplementary Figure S11).
In addition to the analysis of known miRNAs, we also
sought to identify new miRNAs. For this purpose, we
used the miRDeep algorithm to identify miRNAs
without prior information (42). Application of miRDeep
to our sequenced RNA data produced a signiﬁcant pro-
portion of predicted miRNAs (>60%) that were known
and validated. Clustering and additional ﬁltering methods
resulted in the identiﬁcation of 13 putative novel miRNAs
in this study, three of which were the subject of further
conﬁrmatory analysis. Indeed, expression of these
miRNAs was conﬁrmed in a larger NB-cohort (n=70)
using RT-qPCR, with two of the three miRNAs being
associated with clinical course. However, the functional
implication of these novel putative miRNAs in NB
tumor biology remains to be explored.
We detected expression diﬀerences of miRNAs between
favorable and unfavorable NB, including diﬀerential ex-
pression of previously known oncogenic and tumor-
suppressive miRNAs. Based on our results, it can be
expected that miRNA proﬁling will also be of general
value for assessment of aggressiveness in other tumor
entities. Our data provide absolute miRNA expression
counts and novel insights into the correlation of miR/
miR* expression as well as addressing the phenomenon
of miRNA editing in a variety of isomiRs. The functional
implication of miRNA editing in tumor biology warrants
further analysis. We conclude that NGS is a valid tool to
explore the quantitative and qualitative diﬀerences in the
small RNA transcriptomes of primary tumors.
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